<a href="https://laohu8.com/S/KALA">Kala Bio</a> Faces Nasdaq Delisting Risk Over Market Value Compliance
Kala Bio Inc. has announced that it received a deficiency letter from the Nasdaq Stock Market, indicating that the company is not in compliance with Nasdaq Listing Rule 5550(b)(2). The rule requires a minimum market value of listed securities of $35 million, which Kala Bio failed to meet for 30 consecutive business days. The company also does not meet alternative continued listing standards, including minimum stockholders' equity or net income requirements. Kala Bio has been given 180 calendar days, until May 11, 2026, to regain compliance. If compliance is not achieved by the deadline, the company's securities may be subject to delisting, though Kala Bio would have the right to appeal the decision. The company intends to monitor its situation and consider available options to regain compliance with Nasdaq rules.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-110316), on November 12, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。